Navigation Links
Alexza Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
Date:11/21/2013

MOUNTAIN VIEW, Calif., Nov. 21, 2013 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the Company will participate in the 25th Annual Piper Jaffray Healthcare Conference, being held in New York, NY, on December 3 - 4, 2013.  Thomas B. King, Alexza President and CEO, will present at the conference.  The Alexza corporate presentation will be Tuesday, December 3, 2013 at 2:30 p.m. Eastern Time.  The presentation will be webcast live.

To access the presentation via the Web, please go to the Alexza Investor Relations tab at www.alexza.com or at http://www.media-server.com/m/p/ojwv3h6t.  A replay of the webcast will be available approximately 24 hours after the presentation and archived for 30 days.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's products are based on the Staccato system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner.

ADASUVE (Staccato loxapine) is Alexza's first commercial product, which was approved by the U.S. Food and Drug Administration in December 2012 and by the European Commission in February 2013.  Teva Pharmaceuticals USA, Inc. is Alexza's commercial partner for ADASUVE in the U.S.  Grupo Ferrer Internacional, S.A. is Alexza's commercial partner for ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.  For more information about ADASUVE, please visit www.adasuve.com

ADASUVE® and Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the ability of Alexza and our partners, Teva and Ferrer, to effectively and profitably commercialize ADASUVE, estimated product revenues and royalties associated with the sale of ADASUVE, the adequacy of the Company's capital to support the Company's operations, and the Company's ability to raise additional funds and the potential terms of such potential financings. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
2. Alexza Receives Complete Response Letter for Adasuve™ NDA
3. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexza Pharmaceuticals Inc.
4. Alexza Announces Reverse Stock Split in Order to Maintain NASDAQ Listing
5. Alexza Secures a $20 Million Committed Equity Financing Facility with Azimuth Opportunity, L.P.
6. Alexza Announces Management Promotions
7. Alexza Reports 2012 Second Quarter Financial Results and Provides Business Update
8. Alexza Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference
9. Alexza Pharmaceuticals Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences
10. Alexza to Report 2012 Year-End Financial Results on Tuesday, March 26, 2013
11. Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... May 25, 2016 According to ... Type (3D, 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic ... User (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast to ... Medical Animation Market for the forecast period of 2016 ... 301.3 Million by 2021 from USD 117.3 Million in ...
(Date:5/25/2016)... YORK , May 25, 2016  According to ... reached $381 billion in 2015.  Though these are ... plenty of opportunity for success for companies that ... in search of new growth prospects medical device ... on research and development (R&D) than do companies ...
(Date:5/25/2016)... May 25, 2016 Digital Health Dialog, ... it by the US Patent and Trademark Office ... includes proprietary processes for electronic opt-­in and processing ... wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for individuals ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... The Global Wellness Summit ... ten predictions on the future of wellness, travel, spa and beauty in Europe. The ... and beauty companies to leading economists and researchers - to forecast where wellness is ...
(Date:5/31/2016)... , ... May 31, 2016 , ... The Orthopaedic Research ... committee members: , David G. Lewallen, MD, began his term as president in ... Michael L. Parks, MD, is OREF’s new president-elect. Richard F. Kyle, MD, will serve ...
(Date:5/31/2016)... , ... May 31, 2016 , ... In a recent ... Feiner and broadcast on New Rochelle, NY-based WVOX (1460 AM), leading medical ... what she calls the country’s “modern medical money maelstrom.” , During the interview ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... information technology solutions to the healthcare industry, The University of Scranton is adding ... an accelerated path to a career in rapidly growing field of healthcare information. ...
(Date:5/30/2016)... California (PRWEB) , ... May 30, 2016 , ... ... easy to use inside of FCPX," said Christina Austin - CEO of Pixel ... exclusively for use within Final Cut Pro X. Choose from abstract transitions to ...
Breaking Medicine News(10 mins):